Search





Search





Kyverna Therapeutics Inc

KYTX

Add to Watchlist

6.990USD

-0.080-1.13%

Close 09-24 16:00（ET）

424.99MMarket Cap

LossP/E TTM

Kyverna Therapeutics Inc

6.990

-0.080-1.13%

Financial Summary Income Statement Balance Sheet Cash Flow Statement Revenue Earnings Risk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial Summary Income Statement Balance Sheet Cash Flow Statement Revenue Earnings Risk Assessment

KYTX Cash Flow Statement

You can access the annual and quarterly cash flow statements of Kyverna Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q2

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q1

FY2022Q4

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-26.16%-40.31M

7.39%-41.60M

9.54%-33.53M

-57.59%-43.32M

-32.16%-31.95M

-75.96%-44.91M

-99.65%-37.06M

---27.49M

---24.18M

-122.77%-25.52M

-110.54%-18.56M

---11.46M

---8.82M

Net income from continuing operations

8.94%-38.32M

10.99%-39.73M

-0.84%-37.80M

-6.65%-36.79M

-46.10%-42.08M

-67.22%-44.63M

-81.40%-37.49M

---34.49M

---28.80M

-139.55%-26.69M

-143.26%-20.67M

---11.14M

---8.50M

Operating gains losses

-15.73%434.00K

-69.45%351.00K

-34.64%368.00K

-25.63%415.00K

-2.83%515.00K

138.38%1.15M

21.86%563.00K

--558.00K

--530.00K

22.34%482.00K

23.53%462.00K

--394.00K

--374.00K

Other non-cash items

113.65%154.00K

92.11%-111.00K

60.09%-619.00K

62.40%-835.00K

29.23%-1.13M

-671.54%-1.41M

-927.15%-1.55M

---2.22M

---1.59M

-19.61%246.00K

-153.93%-151.00K

--306.00K

--280.00K

Change in working capital

-174.78%-6.15M

-146.98%-5.39M

5000.00%1.73M

-268.53%-8.85M

86.64%8.23M

-18.82%-2.18M

-96.63%34.00K

--5.25M

--4.41M

-23.94%-1.84M

176.91%1.01M

---1.48M

---1.31M

-Change in prepaid expenses

-125.17%-592.00K

117.37%66.00K

106.95%58.00K

5.33%-1.14M

-24.32%2.35M

85.23%-380.00K

15.23%-835.00K

---1.20M

--3.11M

-1498.14%-2.57M

-207.81%-985.00K

---161.00K

---320.00K

-Change in other current assets

15360.00%1.55M

99.03%-5.00K

150.31%483.00K

-44.49%-958.00K

125.64%10.00K

-75.77%-515.00K

47.02%-960.00K

---663.00K

---39.00K

32.64%-293.00K

-214.58%-1.81M

---435.00K

---576.00K

-Change in other current liabilities

----

-744.59%-2.50M

----

-188.89%-296.00K

--296.00K

----

141.83%333.00K

----

---796.00K

Cash from non-recurring investing activities

Cash from operating activities

-26.16%-40.31M

7.39%-41.60M

9.54%-33.53M

-57.59%-43.32M

-32.16%-31.95M

-75.96%-44.91M

-99.65%-37.06M

---27.49M

---24.18M

-122.77%-25.52M

-110.54%-18.56M

---11.46M

---8.82M

Investing cash flow

Net cash from continuing investing activities

168.63%548.00K

----

0.94%537.00K

215.69%322.00K

-80.16%204.00K

-100.00%0.00

59.28%532.00K

--102.00K

--1.03M

1839.29%543.00K

2683.33%334.00K

--28.00K

--12.00K

Capital expenditures

168.63%548.00K

----

1.13%538.00K

284.31%392.00K

-80.16%204.00K

-100.00%0.00

59.28%532.00K

--102.00K

--1.03M

1839.29%543.00K

2683.33%334.00K

--28.00K

--12.00K

Net cash flow from disposal of fixed assets

7225.00%293.00K

----

-100.19%-1.00K

-166.67%-68.00K

-99.61%4.00K

-100.00%0.00

59.28%532.00K

--102.00K

--1.03M

1839.29%543.00K

2683.33%334.00K

--28.00K

--12.00K

Net cash flow from intangible asset transactions

27.50%255.00K

----

--538.00K

--390.00K

--200.00K

----

Net cash flow from investment products

24.88%36.68M

-999.98%-50.20M

-156.29%-16.75M

2840.75%22.88M

143.91%29.37M

104.56%5.58M

-7.06%29.75M

--778.00K

---66.89M

-994.07%-122.34M

111.19%32.02M

--13.68M

--15.16M

Net cash flow from other investing activities

---548.00K

--0.00

----

Cash from non-current investing activities

Net cash flow from investing activities

23.87%36.13M

-999.98%-50.20M

-159.16%-17.29M

3236.83%22.56M

142.94%29.17M

104.54%5.58M

-7.76%29.22M

--676.00K

---67.92M

-999.88%-122.88M

109.16%31.68M

--13.65M

--15.15M

Financing cash flow

Cash flow from continuous financing activities

683.67%3.79M

75.60%-101.00K

65561.86%140.74M

1078.95%1.49M

-14.06%-649.00K

-100.12%-414.00K

85.01%-215.00K

---152.00K

---569.00K

234856.25%338.05M

-1305.88%-1.43M

---144.00K

---102.00K

Net cash flow from debt Issuance/repayment

63.74%-95.00K

74.78%-86.00K

10065.59%24.61M

50.41%-120.00K

-11.02%-262.00K

-47.62%-341.00K

-12.79%-247.00K

---242.00K

---236.00K

-37.50%-231.00K

-51.03%-219.00K

---168.00K

---145.00K

Net cash flow from common stock issuance/repurchase

--2.49M

----

--115.91M

--0.00

-100.00%0.00

--0.00

--341.17M

----

--0.00

----

Net cash flow from preferred stock issuance/repurchase

----

--0.00

----

--0.00

Proceeds from stock option exercised by employees

--1.65M

8000.00%243.00K

940.63%333.00K

1734.44%1.65M

-100.00%0.00

-95.31%3.00K

-88.36%32.00K

--90.00K

--73.00K

166.67%64.00K

539.53%275.00K

--24.00K

--43.00K

Net cash flow from other financing activities

33.59%-257.00K

-239.47%-258.00K

---113.00K

---43.00K

4.68%-387.00K

97.43%-76.00K

100.00%0.00

--0.00

---406.00K

---2.96M

---1.49M

--0.00

----

Net cash from non-recurrent financing activities

Net cash from financing activities

683.67%3.79M

75.60%-101.00K

65561.86%140.74M

1078.95%1.49M

-14.06%-649.00K

-100.12%-414.00K

85.01%-215.00K

---152.00K

---569.00K

234856.25%338.05M

-1305.88%-1.43M

---144.00K

---102.00K

Net cash flow

Beginning cash balance

-42.97%32.74M

28.27%124.64M

-67.01%34.72M

-59.16%53.99M

-74.46%57.42M

175.97%97.17M

347.24%105.23M

--132.19M

--224.86M

-8.04%35.21M

--23.53M

--38.29M

--0.00

Current period cash flow changes

88.69%-388.00K

-131.19%-91.90M

1216.58%89.93M

28.51%-19.28M

96.30%-3.43M

-120.96%-39.75M

-168.93%-8.05M

---26.96M

---92.67M

9137.46%189.65M

87.60%11.68M

--2.05M

--6.23M

Ending cash balance

-40.07%32.36M

-42.97%32.74M

28.27%124.64M

-67.01%34.72M

-59.16%53.99M

-74.46%57.42M

175.97%97.17M

--105.23M

--132.19M

457.38%224.86M

465.38%35.21M

--40.34M

--6.23M

Free cash flow

-27.06%-40.85M

7.39%-41.60M

9.38%-34.06M

-58.43%-43.71M

-27.58%-32.15M

-72.30%-44.91M

-98.94%-37.59M

---27.59M

---25.20M

-126.95%-26.07M

-114.03%-18.90M

---11.49M

---8.83M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Kyverna Therapeutics Inc Generate?



Kyverna Therapeutics Inc generated -153.71M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Kyverna Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Kyverna Therapeutics Inc's operating cash flow increased by -34.54% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Kyverna Therapeutics Inc Spend on Capital Expenditures?



Kyverna Therapeutics Inc spent 1.13M on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Kyverna Therapeutics Inc's Financing Cash Flow Changed?



Kyverna Therapeutics Inc used 141.17M in financing activities in the latest quarter.

What is free cash flow and why does it matter for KYTX?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Kyverna Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -154.84M reflecting a -32.97% change from the previous year.